On April 15, 2025 Artios Pharma Limited ("Artios"), a clinical-stage biotech company led by pioneers of DNA damage response ("DDR") drug development, reported that the company’s abstract featuring clinical trial results from its ongoing Phase 1/2a study of ART0380 in combination with low dose irinotecan has been selected for an oral presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) ("AACR") Annual Meeting 2025, taking place in Chicago from April 25 to 30, 2025 (Press release, Artios Pharma, APR 15, 2025, View Source [SID1234651932]). Artios will also present posters on preclinical data from its ART0380 and ART6043 programs.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the oral presentation:
Abstract Title: First results of ART0380 (an ATR kinase inhibitor) with low dose irinotecan in advanced or metastatic tumors
Presenter: Susanna Ulahannan, MD, Associate Professor, Stephenson Cancer Center at the University of Oklahoma/SCRI, OK, USA
Date: Tuesday, April 29, 2025
Time: 3:50 pm – 4:00 pm CDT
Location: Room S406 (Vista Ballroom) – McCormick Place South (Level 4)
Details of the poster presentation on ART0380:
Abstract Title: Combination of the ATR inhibitor, ART0380, with irinotecan for treating ATM-negative tumors
Presenter: Helen M. R. Robinson, VP of Biology, Artios
Session: PO.ET06.02 – DNA Damage Response and Modulation of DNA Repair 1
Date Monday, April 28, 2025
Time: 2:00 pm – 5:00 pm CDT
Location: Section 16
The full poster abstract is available on the AACR (Free AACR Whitepaper) Annual Meeting website.
Details of the poster presentation on ART6043:
Abstract Title: DNA polymerase theta inhibitor, ART6043, potentiates the efficacy of 177Lu- and 225Ac-based radioligand therapies in vitro and in vivo
Presenter: Marco Ranzani, Associate Director, Artios
Session: PO.ET06.02 – DNA Damage Response and Modulation of DNA Repair 1
Date Monday, April 28, 2025
Time: 2:00 pm – 5:00 pm CDT
Location: Section 16
The full poster abstract is available on the AACR (Free AACR Whitepaper) Annual Meeting website.